Preview

Кардиология

Расширенный поиск

Фибрилляция предсердий и когнитивные нарушения: особенности взаимосвязи, механизмов развития и профилактики

https://doi.org/10.18087/cardio.2022.1.n1904

Полный текст:

Аннотация

В статье обсуждаются вопросы развития когнитивного дефицита у пациентов с фибрилляцией предсердий (ФП), приводятся данные о механизмах развития когнитивных нарушений на фоне ФП. Обсуждается вопрос о возможном снижении риска когнитивных нарушений на фоне антикоагулянтной терапии с целью профилактики инсульта при ФП и о том, что разные антикоагулянты обладают различными свойствами, которые могут иметь значение для пациентов. Так, пациенты с когнитивными нарушениями чаще забывают принимать препарат, что может повлечь за собой серьезные, возможно, смертельные последствия. В связи с этим удобство приема препарата может иметь ключевое значение. Препарат ривароксабан, имеющий однократный режим дозирования и календарную упаковку, может позволить пациенту лучше соблюдать рекомендации врача. Таким образом, ривароксабан может помочь соблюдению высокой приверженности к лечению, которая служит главным условием обеспечения комплексной защиты пожилого пациента с ФП, в которой он нуждается, включая также: защиту от инсульта при высоких показателях безопасности, снижение риска развития коронарных осложнений и ухудшения функции почек.

 

Об авторах

А. Я. Ковалева
ФГБНУ "Институт химической биологии и фундаментальной медицины" СО РАН, Новсибирск
Россия

врач-кардиолог, м.н.с. лаборатории персонализированной медицины ИХБФМ СО РАН



В. Л. Лукинов
Институт вычислительной математики и математической геофизики СО РАН, Новосибирск
Россия

старший научный сотрудник, зав. лаборатории численного анализа стохастических дифференциальных уравнений

 



Г. И. Лифшиц
ФГБНУ "Институт химической биологии и фундаментальной медицины" СО РАН, Новсибирск
Россия

Заведующая Лабораторией персонализированной медицины ИХБФМ СО РАН, доктор медицинских наук.

 



Список литературы

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP et al. Heart Disease and Stroke Statistics–2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56–528. DOI: 10.1161/CIR.0000000000000659

2. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–46. DOI: 10.1016/S0140-6736(20)30367-6

3. Hui DS, Morley JE, Mikolajczak PC, Lee R. Atrial fibrillation: A major risk factor for cognitive decline. American Heart Journal. 2015;169(4):448–56. DOI: 10.1016/j.ahj.2014.12.015

4. Saglietto A, Matta M, Gaita F, Jacobs V, Bunch TJ, Anselmino M. Stroke-independent contribution of atrial fibrillation to dementia: a meta-analysis. Open Heart. 2019;6(1):e000984. DOI: 10.1136/ openhrt-2018-000984

5. Liu D-S, Chen J, Jian W-M, Zhang G-R, Liu Z-R. The association of atrial fibrillation and dementia incidence: a meta-analysis of prospective cohort studies. Journal of Geriatric Cardiology. 2019;16(3):298–306. DOI: 10.11909/j.issn.1671-5411.2019.03.006

6. Caplan LR. Atrial Fibrillation, Past and Future: From a Stroke Non-Entity to an Over-Targeted Cause. Cerebrovascular Diseases. 2018;45(3–4):149–53. DOI: 10.1159/000488063 7. Kim AT, Iwata S, Ishikawa S, Tamura S, Matsuo M, Yoshiyama T et al. Difference in risk factors of silent brain infarction between paroxysmal and persistent atrial fibrillation. IJC Heart & Vasculature. 2021;33:100753. DOI: 10.1016/j.ijcha.2021.100753

7. Herm J, Schurig J, Martinek MR, Höltgen R, Schirdewan A, Kirchhof P et al. MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. BMC Cardiovascular Disorders. 2019;19(1):58. DOI: 10.1186/s12872-019-1035-1

8. Hahne K, Mönnig G, Samol A. Atrial fibrillation and silent stroke: links, risks, and challenges. Vascular Health and Risk Management. 2016;12:65–74. DOI: 10.2147/VHRM.S81807

9. Sugioka K, Takagi M, Sakamoto S, Fujita S, Ito A, Iwata S et al. Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: A transesophageal echocardiographic study. American Heart Journal. 2015;169(6):783–90. DOI: 10.1016/j.ahj.2015.03.016

10. Manolis TA, Manolis AA, Apostolopoulos EJ, Melita H, Manolis AS. Atrial Fibrillation and Cognitive Impairment: An Associated Burden or Burden by Association? Angiology. 2020;71(6):498–519. DOI: 10.1177/0003319720910669

11. Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia? EP Europace. 2018;20(3):408–19. DOI: 10.1093/europace/eux031

12. Barber M, Tait RC, Scott J, Rumley A, Lowe GDO, Stott DJ. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. Journal of Thrombosis and Haemostasis. 2004;2(11):1873–8. DOI: 10.1111/j.1538-7836.2004.00993.x

13. Hendriks JM, Gallagher C, Middeldorp ME, Lau DH, Sanders P. Risk factor management and atrial fibrillation. EP Europace. 2021;23(Suppl 2):ii52–60. DOI: 10.1093/europace/euaa346

14. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D et al. Aggressive Risk Factor Reduction Study for Atrial Fibrillation and Implications for the Outcome of Ablation. Journal of the American College of Cardiology. 2014;64(21):2222–31. DOI: 10.1016/j.jacc.2014.09.028

15. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: a long-term follow-up study (LEGACY). Journal of the American College of Cardiology. 2015;65(20):2159–69. DOI: 10.1016/j.jacc.2015.03.002

16. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: the CARDIO-FIT study. Journal of the American College of Cardiology. 2015;66(9):985–96. DOI: 10.1016/j.jacc.2015.06.488

17. Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. EP Europace. 2018;20(12):1929–35. DOI: 10.1093/europace/euy117

18. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nature Reviews Cardiology. 2017;14(11):627–8. DOI: 10.1038/nrcardio.2017.153

19. van Doorn S, Tavenier A, Rutten FH, Hoes AW, Moons KGM, Geersing G-J. Risk of cardiac and non-cardiac adverse events in community-dwelling older patients with atrial fibrillation: a prospective cohort study in the Netherlands. BMJ Open. 2018;8(8):e021681. DOI: 10.1136/bmjopen-2018-021681

20. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. The American Journal of Medicine. 2018;131(11):1359- 1366.e6. DOI: 10.1016/j.amjmed.2018.06.012

21. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort. Mayo Clinic Proceedings. 2019;94(7):1261–7. DOI: 10.1016/j.mayocp.2018.10.022

22. Yoon M, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S et al. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thrombosis and Haemostasis. 2019;119(10):1695–703. DOI: 10.1055/s-0039-1693516

23. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. Journal of the American Heart Association. 2020;9(10):e014932. DOI: 10.1161/JAHA.119.014932

24. Romiti G, Pastori D, Rivera-Caravaca J, Ding W, Gue Y, Menichelli D et al. The Atrial Fibrillation Better Care (ABC) pathway in atrial fibrillation: a systematic review and meta-analysis of 285,000 patients. EP Europace. 2021;23(Suppl 3):euab116.290. DOI: 10.1093/europace/euab116.290

25. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612

26. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883–91. DOI: 10.1056/NEJMoa1009638

27. Hanon O, Vidal J-S, Pisica-Donose G, Orvoën G, David J-P, Chaussade E et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2021;107(17):1376–82. DOI: 10.1136/heartjnl-2020-317923

28. Fox KAA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European Heart Journal. 2011;32(19):2387–94. DOI: 10.1093/eurheartj/ehr342

29. Чашкина М.И., Андреев Д.А., Козловская Н.Л., Салпагарова З.К., Суворов А.Ю., Сучкова С.А. и др. Показатели безопасности ривароксабана по сравнению с варфарином у пациентов с фибрилляцией предсердий и хронической болезнью почек поздних стадий. Кардиология. 2020;60(11):94–100. DOI: 10.18087/cardio.2020.11.n1322

30. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592. DOI: 10.1136/bmjopen-2012-001592

31. Loke YK, Pradhan S, Yeong JK, Kwok CS. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. British Journal of Clinical Pharmacology. 2014;78(4):707–17. DOI: 10.1111/bcp.12376

32. Chatterjee S, Sharma A, Uchino K, Biondi-Zoccai G, Lichstein E, Mukherjee D. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coronary Artery Disease. 2013;24(8):628–35. DOI: 10.1097/MCA.0000000000000031

33. Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology. 2017;70(21):2621–32. DOI: 10.1016/j.jacc.2017.09.1087

34. Coleman CI, Kreutz R, Sood N, Bunz TJ, Meinecke A-K, Eriksson D et al. Rivaroxaban’s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. Clinical and Applied Thrombosis/Hemostasis. 2019;25:107602961986853. DOI: 10.1177/1076029619868535

35. Туров А.Н., Панфилов С.В., Чиглинцева О.В. Эффективность, безопасность и приверженность при использовании новых антикоагулянтов у пациентов с фибрилляцией предсердий старше 75 лет. Рациональная Фармакотерапия в Кардиологии. 2020;16(1):10-8. DOI: 10.20996/1819-6446-2020-20-07

36. Gardarsdottir M, Sigurdsson S, Aspelund T, Rokita H, Launer LJ, Gudnason V et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;20(8):1252–8. DOI: 10.1093/europace/eux220

37. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS et al. Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation. Journal of Cardiovascular Electrophysiology. 2011;22(8):839–45. DOI: 10.1111/j.1540-8167.2011.02035.x

38. Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. European Heart Journal. 2018;39(6):453–60. DOI: 10.1093/eurheartj/ehx579

39. Field TS, Weijs B, Curcio A, Giustozzi M, Sudikas S, Katholing A et al. Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study. Thrombosis and Haemostasis. 2019;119(6):981–91. DOI: 10.1055/s-0039-1683429

40. Mongkhon P, Fanning L, Lau WCY, Tse G, Lau KK, Wei L et al. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: A population-based cohort study. Heart Rhythm. 2020;17(5):706–13. DOI: 10.1016/j.hrthm.2020.01.007

41. Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014;11(12):2206–13. DOI: 10.1016/j.hrthm.2014.08.013

42. Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD et al. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation. The American Journal of Cardiology. 2016;118(2):210–4. DOI: 10.1016/j.amjcard.2016.04.039

43. Søgaard M, Skjøth F, Jensen M, Kjældgaard JN, Lip GYH, Larsen TB et al. Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study. Journal of the American Heart Association. 2019;8(11):e011358. DOI: 10.1161/JAHA.118.011358

44. Chen N, Lutsey PL, MacLehose RF, Claxton JS, Norby FL, Chamberlain AM et al. Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation. Journal of the American Heart Association. 2018;7(21):e009561. DOI: 10.1161/JAHA.118.009561

45. Lin M, Han W, Zhong J, Wu L. A systematic review and meta‐analysis to determine the effect of oral anticoagulants on incidence of dementia in patients with atrial fibrillation. International Journal of Clinical Practice. 2021;75(10):e14269. DOI: 10.1111/ijcp.14269

46. Kim D, Yang P-S, Jang E, Yu HT, Kim T-H, Uhm J-S et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021;23(2):184–95. DOI: 10.1093/europace/euaa192

47. Salas M, In’t Veld BA, van der Linden PD, Hofman A, Breteler В, Breteler ВH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: The Rotterdam Study. Clinical Pharmacology & Therapeutics. 2001;70(6):561–6. DOI: 10.1067/mcp.2001.119812

48. Pastori D, Miyazawa K, Lip GYH. Dementia and Atrial Fibrillation: A Dangerous Combination for Ischemic Stroke and Mortality. Journal of Alzheimer’s Disease. 2018;61(3):1129–32. DOI: 10.3233/JAD170955

49. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021;23(10):1612–76. DOI: 10.1093/europace/euab065

50. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Current Medical Research and Opinion. 2012;28(5):669–80. DOI: 10.1185/03007995.2012.677419

51. Smits E, Holthuis E, Enders D, Spentzouris G, Beier D. Stroke associated with non-adherence and non-persistence with direct oral anticoagulants in Germany. [Internet] Available at: https://esc365.escardio.org/presentation/230677?query=Stroke%20associated%20with%20 non-adherence%20and%20non-persistence%20with%20direct%20oral%20anticoagulants%20in%20Germany

52. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal. 2016;37(14):1145–53. DOI: 10.1093/eurheartj/ehv466

53. Tittl L, Marten S, Naue C, Beyer-Westendorf J. 5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis Research. 2021;202:24–30. DOI: 10.1016/j.thromres.2021.03.004

54. Hecker J, Marten S, Keller L, Helmert S, Michalski F, Werth S et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation: Results from the Dresden NOAC Registry. Thrombosis and Haemostasis. 2016;115(05):939–49. DOI: 10.1160/TH15-10-0840

55. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database of Systematic Reviews. 2011;9:CD005025. DOI: 10.1002/14651858.CD005025.pub3

56. Sexton E, McLoughlin A, Williams DJ, Merriman NA, Donnelly N, Rohde D et al. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. European Stroke Journal. 2019;4(2):160–71. DOI: 10.1177/2396987318825484

57. Hackett ML, Pickles K. Part I: Frequency of Depression after Stroke: An Updated Systematic Review and Meta-Analysis of Observational Studies. International Journal of Stroke. 2014;9(8):1017–25. DOI: 10.1111/ijs.12357

58. Rofes L, Muriana D, Palomeras E, Vilardell N, Palomera E, AlvarezBerdugo D et al. Prevalence, risk factors and complications of oropharyngeal dysphagia in stroke patients: A cohort study. Neurogastroenterology & Motility. 2018;30(8):e13338. DOI: 10.1111/nmo.13338

59. Belozerceva LA, Voronina EN, Kokh NV, Tsvetovskay GA, Momot AP, Lifshits GI et al. Personalized approach of medication by indirect anticoagulants tailored to the patient - Russian context: what are the prospects? EPMA Journal. 2012;3(1):10. DOI: 10.1186/1878-5085-3-10


Рецензия

Для цитирования:


Ковалева А.Я., Лукинов В.Л., Лифшиц Г.И. Фибрилляция предсердий и когнитивные нарушения: особенности взаимосвязи, механизмов развития и профилактики. Кардиология. 2022;62(1):80-88. https://doi.org/10.18087/cardio.2022.1.n1904

For citation:


Kovaleva A.Y., Lukinov V.L., Lifshits G.I. Atrial fibrillation and cognitive impairment: features of the relationship, developmental and prevention mechanisms. Kardiologiia. 2022;62(1):80-88. (In Russ.) https://doi.org/10.18087/cardio.2022.1.n1904

Просмотров: 441


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)